# US 2005/0090672 A1 · Process for the preparation of benzylimidazole derivatives

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2005/0090672 A1
- Document ID: US20050090672A1
- Status: Published application
- Kind: A1
- Application number: 10/969,354
- Filed: 2004-10-21
- Published: 2005-04-28
- Earliest claimed: 2003-10-23
- Assignees: Dipharma S.p.A.
- Inventors: Pietro Allegrini; Gabriele Razzetti; Graziano Castaldi; Vittorio Lucchini
- Web page: https://patentgrep.com/patent/US20050090672A1

## CPC

- C07D 233/70: One oxygen atom
- A61P 9/12: Antihypertensives
- C07C 237/06: having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07D 233/68: Halogen atoms
- C07D 403/10: linked by a carbon chain containing aromatic rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

A process for the preparation of benzylimidazole derivatives useful as intermediates for preparation of losartan, novel intermediates for their preparation and a process for the preparation of losartan.

## Claims

### Claim 1

A process for the preparation of compounds of formula (II)
wherein Y is a leaving group, comprising chloroformylation of a compound of formula (III)
wherein Y is as defined above, to obtain a compound of formula (IV)
wherein Y is as defined above, and reduction of the aldehyde group to alcohol.

### Claim 2 (depends on 1)

A process according to claim 1, wherein the leaving group is a halogen atom or a hydroxy group activated to esterification.

### Claim 3 (depends on 1)

A process according to claim 1, wherein the chloroformylation reaction is carried out by treatment with phosphorous oxychloride and dimethylformamide, or with a N,N-dimethylformamide dialkylacetal and phosphorous oxychloride.

### Claim 4 (depends on 3)

A process according to claim 3, wherein the reaction is carried out in an inert organic solvent, the formylation phase is carried out at a temperature ranging from −50 to 100° C. and the chlorination phase is carried out at a temperature ranging from 50 to 150° C.

### Claim 5 (depends on 1)

A process according to claim 1, wherein the reduction of the aldehyde group is carried out by treatment with an alkali metal borohydride.

### Claim 6 (depends on 1)

A process according to claim 1, wherein a compound of formula (III) is obtained by reacting a compound of formula (V)
wherein Y is as defined in claim 1, with a trialkyl orthovalerate.

### Claim 7 (depends on 6)

A process according to claim 6, wherein the stoichiometric ratio between a compound of formula (V) and a trialkyl orthovalerate ranges from 1/1 to 1/1.2 and the reaction is carried out in the presence of a catalytic amount of an acid.

### Claim 8 (depends on 6)

A process according to claim 6, wherein the compound of formula (III) is not isolated.

### Claim 9

A compound of formula (III)
wherein Y is a leaving group.

### Claim 10

A compound of formula (V)
wherein Y is a leaving group other than chlorine.

### Claim 11 (depends on 1)

A process for the preparation of losartan or a pharmaceutically acceptable salt thereof comprising:
reaction of a compound of formula (II),
wherein Y is a leaving group,
, with a synthon of formula (VI)
wherein Q is a tetrazole-protecting group; and Z is a
B(R1R2) group wherein each of R1 and R2, which can be the same or different, is halogen, hydroxy or C1-C4 alkoxy; or Z is a lithium or copper atom, or a halogenated metal;
removal of the protecting group Q; and, if desired,
conversion of losartan in a pharmaceutically acceptable salt thereof;
characterized in that the compound of formula (II) is obtained according to the process of claim 1.
